Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - gemcitabine hydrochloride, quantity: 227.705 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: sodium acetate; hydrochloric acid; sodium hydroxide; water for injections - treatment of patients with locally advanced or metastatic non-small celll lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with 5-fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combinatin with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combinatin with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - gemcitabine hydrochloride - solution for infusion - 38mg/1ml

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - gemcitabine hydrochloride - solution for infusion - 38mg/1ml

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - gemcitabine hydrochloride - solution for infusion - 38mg/1ml

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 2277 mg (equivalent: gemcitabine, qty 2000 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; hydrochloric acid; mannitol; sodium hydroxide - gemicor is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemicor is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemicor is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemicor in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemicor in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 2277 mg (equivalent: gemcitabine, qty 2000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium acetate trihydrate; sodium hydroxide - gemcidrox is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcidrox is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemcidrox is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcidrox in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcidrox in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 227.71 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; hydrochloric acid; mannitol; sodium hydroxide - gemicor is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemicor is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemicor is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemicor in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemicor in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 1138.52 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; hydrochloric acid; sodium hydroxide; mannitol - gemicor is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemicor is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemicor in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemicor in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 227.71 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: sodium acetate trihydrate; mannitol; hydrochloric acid; sodium hydroxide - gemcidrox is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcidrox is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. ,gemcidrox is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcidrox in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcidrox in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - gemcitabine hydrochloride, quantity: 1138.52 mg (equivalent: gemcitabine, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium acetate trihydrate; sodium hydroxide - gemcidrox is indicated for treatment of patients with locally advanced or metastatic non-small cell lung cancer. ,gemcidrox is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. gemcitabine drla is also indicated for patients with 5-fu refractory pancreatic cancer. ,gemcitabine alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. ,gemcidrox in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ,gemcidrox in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum?based therapy.